Not Signed In - Barr Confirms Patent Challenge Of Razadyne(R) ER Capsules
Sat, 08 Jul 2006 06:00 AM EST
... BarrPharmaceuticals, Inc. (NYSE: BRL) today confirmed that JanssenPharmaceutica N.V., Janssen, L.P., Ortho-McNeil Neurologics, Inc. andSynaptech, Inc. ("Plaintiff") filed suit against it and its subsidiary,Barr Laboratories, Inc., relating to the patent protecting Razadyne(R) ER(Galantamine Hydrobromide Extended-Release Capsules), 8 mg, 16 mg and 24mg. [click link for full article] ...
Related Topics
- Epstein Barr Virus
- Brompheniramine and Pseudoephedrine Extended Release
- Fenofibrate Capsules
- Cyanocobalamin Capsules
- Casanthranol and Docusate Sodium
- Phenylephrine and Guaifenesin Capsules
- Sulfinpyrazone Capsules
- Patent Lean
- Methylphenidate ER
- Patent Ductus Arteriosus
- Patent foramen ovale
- Nizatidine capsules
- Cromolyn Inhalation Capsules
- Divalproex
- Frequent infections especially with Epstein-Barr virus
- Epstein-Barr Virus (EBV) Infection
- Metronidazole Extended Release
- Niacin Extended Release
- Vancomycin Capsules
- Glipizide
email this page
print this page
bookmark this page
feedback on this page
